Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Rhythm Pharmaceuticals Inc
RYTMCurrent price
52.04 USD
-2.19 USD (-4.04%)
Last closed
55.21 USD
Company
www.rhythmtx.com
ISIN
US76243J1051
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
3 395 504 896 USD
Yield for 12 month
+31.25 %
1Y
3Y
5Y
10Y
15Y
RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Address: 222 Berkeley Street, Boston, MA, United States, 02116
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
72.50 USDP/E ratio
–Dividend Yield
–Current Year
+77 428 000 USD
Last Year
+23 638 000 USD
Current Quarter
+33 251 000 USD
Last Quarter
+29 078 000 USD
Current Year
+68 126 000 USD
Last Year
+21 505 000 USD
Current Quarter
+29 423 000 USD
Last Quarter
+25 954 000 USD
Key Figures RYTM
1 year
3 years
5 years
10 years
EBITDA
-263 916 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-46.24 %
PEG Ratio
–
Return On Equity TTM
-147.90 %
Wall Street Target Price
72.50 USD
Revenue TTM
112 530 000 USD
Book Value
0.18 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
47.80 %
Dividend Yield
–
Gross Profit TTM
21 505 000 USD
Earnings per share
-4.32 USD
Diluted Eps TTM
-4.32 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-230.11 %
Dividend Analytics RYTM
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History RYTM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation RYTM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
27.55
Price Sales TTM
30.17
Enterprise Value EBITDA
-12.65
Price Book MRQ
302.71
Financials RYTM
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators RYTM
For 52 weeks
35.17 USD
68.58 USD
50 Day MA
55.40 USD
Shares Short Prior Month
6 710 030
200 Day MA
46.61 USD
Short Ratio
9.25
Shares Short
6 367 381
Short Percent
15.66 %
BeatStart